Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors

TAMAR TADMOR, GUY MELAMED, HILEL ALAPI, SIVAM GAZIT, TAL PATALON and LIOR ROKACH
Anticancer Research May 2024, 44 (5) 2109-2115; DOI: https://doi.org/10.21873/anticanres.17016
TAMAR TADMOR
1Hematology Unit, Bnai Zion Medical Center, Haifa, Israel;
2Technion International Institute of Technology, Haifa, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Tamar.tadmor@b-zion.org.il
GUY MELAMED
3Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi Tech, Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HILEL ALAPI
3Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi Tech, Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SIVAM GAZIT
3Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi Tech, Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAL PATALON
3Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi Tech, Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LIOR ROKACH
4Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The treatment for chronic lymphocytic leukemia (CLL) has changed dramatically over the last two decades. The current study aimed to investigate the impact on overall survival (OS) and time to next treatment (TTT) among CLL patients from 1998 to 2022. Patients and Methods: The cohort was based on data obtained from electronic medical records of Maccabi, the second largest healthcare organization in Israel. All included patients were diagnosed with CLL based on the IWCLL criteria and complete clinical, laboratory, and treatment data were available. The study encompassed 3,964 patients diagnosed with CLL during the specified study period. Results: Patients with CLL who required therapy were divided into three eras based on the dominant treatment approach: chemotherapy alone before 2010, therapy with chemotherapy and anti-CD20 between 2010 and 2017, and therapy with targeted agents between 2017 and 2022. Median OS was 4.1 years, 7.5 years, and not reached, respectively. The six-year OS rates were 40%, 55%, and 69%, respectively, (p=0.0001). The median time to the next treatment improved from 5.5 years before 2010, to 8.3 between 2010-2017, to not reached after 2017 (p=0.0021). Conclusion: Marked improvements in survival subsequent to fundamental changes in first-line therapy were found in patients with CLL from before 2010 to after 2017.

Key Words:
  • Survival
  • chronic lymphocytic leukemia
  • BTKi
  • BCL2
  • CLL
  • Received February 12, 2024.
  • Revision received March 7, 2024.
  • Accepted March 13, 2024.
  • Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 44 (5)
Anticancer Research
Vol. 44, Issue 5
May 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors
TAMAR TADMOR, GUY MELAMED, HILEL ALAPI, SIVAM GAZIT, TAL PATALON, LIOR ROKACH
Anticancer Research May 2024, 44 (5) 2109-2115; DOI: 10.21873/anticanres.17016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors
TAMAR TADMOR, GUY MELAMED, HILEL ALAPI, SIVAM GAZIT, TAL PATALON, LIOR ROKACH
Anticancer Research May 2024, 44 (5) 2109-2115; DOI: 10.21873/anticanres.17016
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results and Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Two Scoring Tools to Estimate the Risk of Taxane-induced Peripheral Sensory Neuropathy (PNP) in Patients Irradiated for Non-metastatic Breast Cancer
  • Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia
  • Corrigendum
Show more Clinical Studies

Similar Articles

Keywords

  • survival
  • chronic lymphocytic leukemia
  • BTKi
  • BCL2
  • CLL
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire